Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappaB and c-Jun

Biochemical Pharmacology

Volumn 69, Issue 2, 2005, Pages 221-232

  Huang, Shiu Chen ^a   Ho, Chi Tang ^b   Lin Shiau, Shoei Yn ^a   Lin, Jen Kun ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

c Jun; Carnosol; Invasion; Matrix metalloproteinases; Metastasis; Nuclear factor B(NF B)

Indexed keywords

CARNOSOL; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PHENANTHRENE DERIVATIVE; PLANT EXTRACT; PROTEIN C JUN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; IN VITRO STUDY; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ZYMOGRAPHY; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL MELANOMA; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; PLANT LEAF; ROSEMARY;

ANIMALS; ANTINEOPLASTIC AGENTS; DITERPENES, ABIETANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PHENANTHRENES; PLANT EXTRACTS; PLANT LEAVES; PROTO-ONCOGENE PROTEINS C-JUN; ROSMARINUS;

EID: 13844272556     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.09.019     Document Type: Article

References (48)

1. Zeng HH, Tu PF, Zhou K, Wang H, Wang BH, Lu JF. Antioxidant properties of phenolic diterpenes from Rosmarinus officinalis. Acta Pharmacol Sin 2001;22(12):1094-8.
2. Lo AH, Liang YC, Lin-Shiau SY, Ho CT, Lin JK. Carnosol, an antioxidant in rosemary, suppresses inducible nitric oxide synthase through down-regulating nuclear factor-kappaB in mouse macrophages. Carcinogenesis 2002;23(6):983-91.
3. Ito N, Fukushima S, Hagiwara A, Shibata M, Ogiso T. Carcinogenicity of butylated hydroxyanisole in F344 rats. J Natl Cancer Inst 1983;70(2):343-52.
4. Marrero JG, Andres LS, Luis JG. Semisynthesis of rosmanol and its derivatives. Easy access to abietatriene diterpenes isolated from the genus Salvia with biological activities. J Nat Prod 2002;65(7):986-9.
5. Sotelo-Felix JI, Martinez-Fong D, Muriel De la Torre P. Protective effect of carnosol on CCl(4)-induced acute liver damage in rats. Eur J Gastroenterol Hepatol 2002;14(9):1001-6.
6. Singletary KW, Nelshoppen JM. Inhibition of 7,12-dimethylbenz[a] anthracene (DMBA)-induced mammary tumorigenesis and of in vivo formation of mammary DMBA-DNA adducts by rosemary extract. Cancer Lett 1991;60(2):169-75.
7. Chan MM, Ho CT, Huang HI. Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Cancer Lett 1995;96(1):23-9.
8. Offord EA, Mace K, Avanti O, Pfeifer AM. Mechanisms involved in the chemoprotective effects of rosemary extract studied in human liver and bronchial cells. Cancer Lett 1997;114(1-2):275-81.
9. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89(17):1260-70.
10. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000;6(4):149-56.
11. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93(3):178-93.
12. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003;1(6):420-7.
13. Kirstein M, Sanz L, Quinones S, Moscat J, Diaz-Meco MT, Saus J. Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene. J Biol Chem 1996;271(30):18231-6.
14. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997;72(2):155-61.
15. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56(1):190-6.
16. Liotta LA, Abe S, Robey PG, Martin GR. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 1979;76(5):2268-72.
17. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273(26):16501-8.
18. Sopata I, Dancewicz AM. Presence of a gelatin-specific proteinase and its latent form in human leucocytes. Biochim Biophys Acta 1974;370(2):510-23.
19. Gum R, Wang H, Lengyel E, Juarez J, Boyd D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 1997;14(12):1481-93.
20. Himelstein BP, Canete-Soler R, Bernhard EJ, Muschel RJ. Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci 1994;107(Pt 2):477-86.
21. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 2001;91(4):822-32.
22. Purcell WT, Rudek MA, Hidalgo M. Development of matrix metalloproteinase inhibitors in cancer therapy. Hematol Oncol Clin North Am 2002;16(5):1189-227.
23. Bloomston M, Zervos EE, Rosemurgy 2nd AS. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002;9(7):668-74.
24. Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, et al. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 1994;54(3):701-8.
25. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994;269(7):4705-8.
26. Masure S, Nys G, Fiten P, Van Damme J, Opdenakker G. Mouse gelatinase B. cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur J Biochem 1993;218(1):129-41.
27. Chen YC, Kuo TC, Lin-Shiau SY, Lin JK. Induction of HSP70 gene expression by modulation of Ca(+2) ion and cellular p53 protein by curcumin in colorectal carcinoma cells. Mol Carcinog 1996;17(4):224-34.
28. Price JE. Clonogenicity and experimental metastatic potential of spontaneous mouse mammary neoplasms. J Natl Cancer Inst 1986;77(2):529-35.
29. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99(2):157-66.
30. Salo T, Liotta LA, Tryggvason K. Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. J Biol Chem 1983;258(5):3058-63.
31. Ho LL, Chen WJ, Lin-Shiau SY, Lin JK. Penta-O-galloyl-beta-D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1. Eur J Pharmacol 2002;453(2-3):149-58.
32. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 2001;61(5):1855-61.
33. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13(8):781-92.
34. Bischof P, Meisser A, Campana A. Control of MMP-9 expression at the maternal-fetal interface. J Reprod Immunol 2002;55(1-2):3-10.
35. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 1994;54(7 Suppl.):2015s-24s.
36. Offord EA, Gautier JC, Avanti O, Scaletta C, Runge F, Kramer K, et al. Photoprotective potential of lycopene, beta-carotene, vitamin E, vitamin C and carnosic acid in UVA-irradiated human skin fibroblasts. Free Radic Biol Med 2002;32(12):1293-303.
37. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73(1):161-95.
38. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9(2):180-6.
39. Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, et al. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 2001;20(56):8066-74.
40. Ata N, Oku T, Hattori M, Fujii H, Nakajima M, Saiki I. Inhibition by galloylglucose (GG6-10) of tumor invasion through extracellular matrix and gelatinase-mediated degradation of type IV collagens by metastatic tumor cells. Oncol Res 1996;8(12):503-11.
41. Cheng XW, Kuzuya M, Kanda S, Maeda K, Sasaki T, Wang QL, et al. Epigallocatechin-3-gallate binding to MMP-2 inhibits gelatinolytic activity without influencing the attachment to extracellular matrix proteins but enhances MMP-2 binding to TIMP-2. Arch Biochem Biophys 2003;415(1):126-32.
42. Fini ME, Bartlett JD, Matsubara M, Rinehart WB, Mody MK, Girard MT, et al. The rabbit gene for 92-kDa matrix metalloproteinase. Role of AP1 and AP2 in cell type-specific transcription. J Biol Chem 1994;269(46):28620-8.
43. Huang C, Ma WY, Dong Z. Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol Cell Biol 1996;16(11):6427-35.
44. Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998;58(6): 1135-9.
45. Simon C, Hicks MJ, Nemechek AJ, Mehta R, O'Malley Jr BW, Goepfert H, et al. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer 1999;80(9):1412-9.
46. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8(2):395-405.
47. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000;59(3):245-54.
48. Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 1993;53(10 Suppl.): 2208-11.